MX9603452A - Derivados de prostaglandina. - Google Patents

Derivados de prostaglandina.

Info

Publication number
MX9603452A
MX9603452A MX9603452A MX9603452A MX9603452A MX 9603452 A MX9603452 A MX 9603452A MX 9603452 A MX9603452 A MX 9603452A MX 9603452 A MX9603452 A MX 9603452A MX 9603452 A MX9603452 A MX 9603452A
Authority
MX
Mexico
Prior art keywords
prostaglandin
liposome formulations
ester
medicine
formulations containing
Prior art date
Application number
MX9603452A
Other languages
English (en)
Inventor
Akio Nishiura
Takuya Seko
Ryoji Matsumoto
Shin-Ichi Hamano
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX9603452A publication Critical patent/MX9603452A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a los derivados de éster de la prostaglandina E1 de la formula (I): en donde R es (i) -CH2CH2-O-CO-R1, o (ii) -CH2CH2-O-CO-CH2-O-R2, y R1 Y R2 son cada uno independientemente alquilo con C10-20; y a los clatratos de ciclodextrina de los mismos, a las formulaciones de liposoma que los contienen, a los procedimientos para su preparacion y a las composiciones farmacéuticas que los contienen como ingrediente activo. Los compuestos de la formula (I) tienen el efecto de incrementar el flujo sanguíneo y son utiles para la prevencion y/o el tratamiento de desordenes circulatorios periféricos, la ulcera por decubito, o las ulceras de la piel, o para el mantenimiento del flujo sanguíneo.
MX9603452A 1995-08-16 1996-08-16 Derivados de prostaglandina. MX9603452A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23076395 1995-08-16

Publications (1)

Publication Number Publication Date
MX9603452A true MX9603452A (es) 1997-03-29

Family

ID=16912888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603452A MX9603452A (es) 1995-08-16 1996-08-16 Derivados de prostaglandina.

Country Status (16)

Country Link
US (1) US5690957A (es)
EP (1) EP0758645B1 (es)
KR (1) KR100225689B1 (es)
CN (1) CN1058706C (es)
AT (1) ATE185559T1 (es)
AU (1) AU708905B2 (es)
CA (1) CA2183486C (es)
DE (1) DE69604631T2 (es)
DK (1) DK0758645T3 (es)
ES (1) ES2140032T3 (es)
GR (1) GR3032274T3 (es)
HU (1) HUP9602262A3 (es)
MX (1) MX9603452A (es)
NO (1) NO309086B1 (es)
TW (1) TW367324B (es)
ZA (1) ZA966934B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113310A2 (en) * 2005-04-13 2006-10-26 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
EP2156848A4 (en) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd NANOPARTICLE CONTAINING A LOW MOLECULAR WEIGHT DRUG HAVING A NEGATIVELY PROLONGED RELEASE GROUP
ITCA20080017A1 (it) * 2008-07-31 2010-02-01 Giuseppe Brotzu Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari.
KR20110095887A (ko) * 2008-11-18 2011-08-25 가부시키가이샤 엘티티 바이오파마 신규 프로스타글란딘 ｅ１ 유도체 및 그것을 봉입하는 나노 입자
NZ596555A (en) * 2009-05-27 2014-01-31 Univ Osaka Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
CN102028696B (zh) * 2009-09-24 2013-02-13 上海天伟生物制药有限公司 一种前列腺素类化合物的用途
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
JPS59206349A (ja) * 1983-05-10 1984-11-22 Green Cross Corp:The プロスタグランジンｅ↓１誘導体

Also Published As

Publication number Publication date
TW367324B (en) 1999-08-21
HUP9602262A2 (en) 1997-05-28
NO963408L (no) 1997-02-17
AU6210596A (en) 1997-02-20
DE69604631D1 (de) 1999-11-18
AU708905B2 (en) 1999-08-12
DE69604631T2 (de) 2000-02-17
HU9602262D0 (en) 1996-10-28
EP0758645A1 (en) 1997-02-19
ES2140032T3 (es) 2000-02-16
EP0758645B1 (en) 1999-10-13
KR970010742A (ko) 1997-03-27
ZA966934B (en) 1997-02-19
KR100225689B1 (ko) 1999-10-15
CA2183486A1 (en) 1997-02-17
ATE185559T1 (de) 1999-10-15
CN1151398A (zh) 1997-06-11
DK0758645T3 (da) 1999-12-27
GR3032274T3 (en) 2000-04-27
CN1058706C (zh) 2000-11-22
NO309086B1 (no) 2000-12-11
NO963408D0 (no) 1996-08-15
CA2183486C (en) 2002-03-26
US5690957A (en) 1997-11-25
HUP9602262A3 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
MX9603452A (es) Derivados de prostaglandina.
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
DE3462894D1 (de) 3-indolecarboxamide compounds
AU1458495A (en) Application of riluzole in the treatment of mitochondrial diseases
CA2210365A1 (fr) Nouveau derive de l'acide kojique et son utilisation comme agent depigmentant
IL67970A0 (en) Psoralen derivatives,their preparation and pharmaceutical and cosmetic compositions containing them
GR3033195T3 (en) Prostaglandin derivatives
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
ZA939153B (en) Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development
ES2171749T3 (es) Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
DE59305822D1 (de) Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
ES2134441T3 (es) Benzonitrilos terapeuticos.
EP0218195A3 (en) Bis(dibenzo[b,d]pyranyloxy)propanes
BG95739A (en) Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours
ITMI951943A0 (it) Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv
WO1999064063A3 (de) Collagenase-applikationsform